Pipeline

Overview of the REACT® Clinical Program

Lead Platform Programs*

  • Preclin
  • IND
  • Ph 1
  • Ph 2
  • Ph 3
  • Approv
  • Preclinical
  • IND
  • Phase 1
  • Phase 2
  • Phase 3
  • Approval

REACT®/DKD

Diabetes Type II – Prevent/Delay CKD 3/4 

(20-50 ml/min/1.73m2, N=81)
Fully Enrolled

Diabetes Type II – Prevent/Delay CKD 3/4

(20-50 ml/min/1.73m2, N=1,200)
Enrolling in US

Diabetes Type II –
Delay CKD 4/5 

(14-20 ml/min/1.73m2, N=10)
Trial completed

Diabetes Repeat Dose Prevent/Delay CKD 3/4 

(20-50 ml/min/1.73m2, N=50)
enrollment completed
  • Preclinical
  • IND
  • Phase 1
  • Phase 2
  • Phase 3
  • Approval

REACT®/CAKUT

Congenital Anomalies – Prevent/Delay N=15

trial completed

Footnotes:

† injecting both kidneys w/ redose trigger

‡ Increased from 30 as indicated in Proxy Amendment No. 1, page 289

Preliminary Safety Profile

To date, rilparencel appears to be well tolerated in patients injected, and no adverse events related to rilparencel have been observed. The rilparencel safety profile will continue to be closely monitored in ongoing clinical trials.